Baxter International Inc
BAX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$42.00 | Yxytsbs | Wslfsjrn |
Baxter: Cuts Into Valuation by Selling Kidney Care Segment at a Discount to Intrinsic Value
Narrow-moat Baxter announced plans to sell its kidney care segment to Carlyle, a private equity investor, for $3.8 billion. To reflect the planned divestiture of its kidney care segment below intrinsic value, we are reducing our fair value estimate on Baxter to $62 per share from $67 previously. Baxter shares remain materially undervalued.